Measurement of lung fungction  is a way to determine the effectiveness of a given therapy. A monitoring asthma symptoms is to see the value of peak expiratory flow (PEF) with a peak flow meter. The measurement is objective and can be used to predict the prognosis of asthma through the monitoring of conditions of the lung. This study aims to find out information on the use of a peak flow meter explanations given to the patient’s pharmacist in a pharmacy in a town in East Java. This research method is a non-experimental with cross sectional study. This study uses observation techniques in the form of a checklist, using the concept of a mysterious patient. Sampling by the proportional method, and then the data will be processed descriptively. The research sample of 80 pharmaceutical personnel consisting of 33 pharmacists and 47 non-pharmacists. In the group of non-pharmacists and pharmacists, the points most overlooked is the explanation of the recording of the results (number 6) and compared with the best value (number 8). Pharmacists still need to improve in understanding the basics and techniques in order to use a peak flow meter can help asthma patients to monitor their asthma medication

ABSTRACT Treatment of respiratory disorders using a metered-dose inhaler (MDI) with spacer becomes one of the important points. Pharmacists at pharmacies are the final key in therapy to ascertain how the use of inhalation tools is correct. This study aims to determine the completeness of each step of information on how to use MDI with spacer given by pharmacists at pharmacies in East Surabaya. The research design used is cross-sectional study with the subject of research is pharmacist in pharmacy. The research variable is the explanation of how to use MDI inhaler with spacer. An assessment method of 8 steps on how to use MDI with spacer and each number gets a value. Research subjects were 22 pharmacists. Most pharmacists describe each step orally by using the tool directly, ie at step: 1a (77.27%), 1b (77.27%), 2 (81.81%), 3 (31.81%) , 4a (59.09%), 4b (13.63%), 5a (100%), 5b (63.63%), 6a (90.90%), 6b (40.90%), 8a (9 , 09%), and 8b (9.09%). Most of the pharmacists explain verbally with a demonstration tool but only one pharmacist can explain all the steps completely. Therefore, pharmacists need to improve IEC services related to the use of MDI with a spacer for respiratory treatment.   Keywords :   information on how to use inhaler, Metered-Dose Inhaler (MDI), spacer, pharmacist, pharmacy

AbstrakPencampuran sediaan parenteral (iv admixture) yang sudah dilaksanakan secara umum di rumah sakit mempunyai kemungkinan terjadinya kegagalan baik berupa inkompatibilitas obat maupun gangguan stabilitas obat. Penelitian ini bertujuan mengetahui angka inkompatibilitas obat dalam pencampuran sediaan parenteral di RSUD Prof. Dr. Margono Soekarjo Purwokerto yang mengalami inkompatibilitas fisika yang teramati secara organoleptis. Penelitian ini merupakan penelitian deskriptif prospektif. Data yang telah dikumpulkan lalu dianalisis secara deskriptif. Dari 667 pencampuran sediaan parenteral di bangsal bedah saraf RSUD Prof. Dr. Margono Soekarjo selama bulan Februari 2010, dapat disimpulkan angka inkompatibilitas potensial sebesar 0,45% dan inkompatibilitas aktual sebesar 2,55%. Inkompatibilitas aktual yang terjadi berupa kristal 0,17%, endapan 0,17%, dan kabut sementara 2,04% pada pencampuran fenitoin dengan NaCl atau ringer laktat. However, it has a possibility of failures, like incompatibilities and changes in drug stabilities. The aim of this study was to determine the rate of drug incompatibilities in mixing parenteral preparations in neurosurgery ward in Prof. Dr. Margono Soekarjo Regional Public Hospital which undergo physical incompatibility observed in organoleptic. This study was a prospective descriptive research for one month period. Data were collected and analyzed descriptively. The results showed that from 667 parenteral admixtures in neurosurgery ward in Prof Dr Margono Soekarjo Hospital in February 2010, there were 0.45% potential incompatibility and 2.55% actual incompatibility happened. Actual incompatibility shown as crystal 0.17%, sediment 0.17%, and 2.04% was non-permanent haze in phenytoin and sodium chloride or ringer lactate admixtures.

Polimorfisme genetik CYP1A2 berkaitan dengan metabolisme teofilin sehingga dapat memengaruhi kadar obat dalam darah serta berpengaruh terhadap kejadian adverse drug reaction (ADR) dan outcome klinis terapi asma. Frekuensi polimorfisme CYP1A2 diketahui bervariasi antar etnis. Diduga populasi Indonesia memiliki frekuensi varian gen CYP1A2*1F yang tinggi. Penelitian ini bertujuan untuk mengetahui profil polimorfisme gen CYP1A2*1F pada sampel nonasma dan asma di Indonesia dengan populasi lain berdasarkan literatur. Pengambilan data dilakukan pada Januari-Juni 2014. Sampel darah diperoleh dari 29 orang nonasma dan 16 pasien asma. Setelah dilakukan ekstraksi DNA genomik kemudian ditentukan polimorfisme gen CYP1A2*1F dengan metode PCR-RFLP. Hasil penelitian ini menunjukkan bahwa polimorfisme gen CYP1A2*1F pada sampel nonasma adalah 10,35% (3/29) untuk C/C, 37,93% (11/29) untuk C/A dan 51,72% (15/29) untuk A/A. Pada penderita asma frekuensi distribusi genotip C/A sebesar 81,25% (13/16) dan A/A sebesar 18,75% (3/16). Tidak terdapat perbedaan signifikan (p=0,276) frekuensi alel antara sampel nonasma dan pasien asma. Frekuensi gen CYP1A2*1F pada populasi Indonesia lebih besar dibandingkan dengan populasi Mesir, Jepang, dan Inggris akan tetapi lebih rendah dibandingkan dengan Malaysia. Oleh karena itu, dapat disimpulkan tidak terdapat perbedaan frekuensi.

Telah dilakukan penelitian untuk mempelajari farmakokinetika dari teofilina setelahpemberian oral dosis tunggal tablet teofilina dan aminofilina lepas kendali pada subyek normal. Ta–blet teofilina (dosis 300 mg) dan aminofilina (dosis 350 mg) lepas kendali diberikan dalam bentukoral dosis tunggal, pada pria normal (20-30 tahun, 50-75 kg), tidak merokok, dengan fungsi paruparu,hati, ginjal dan jantung normal. Kadar teofilina serum ditentukan dengan metode FlourescencePolarization Immunoassay (FPIA). Parameter farmakokinetika yang diamati meliputi: t maks, Cpmaks, AUC, tetapan laju absorpsi (Ka) dan eliminasi (K) serta t ½ eliminasi. Hasil penelitian menunjukkanbahwa profil kurva kadar teofilina serum terhadap waktu untuk tablet teofilina (AUC=97,56μg/ml jam, Cp maks=5,83 μg/ml, Ka=0,209 jam-1, t maks=4 jam, K=0,080 jam-1, dan t½=8,87 jam)dan aminofilina (AUC=121,93 μg/ml jam, Cp maks=6,70 μg/ml, Ka=0,239 jam-1, t maks=6,8 jam,K=0,061 jam-1, dan t½=11,51 jam) lepas kendali sesuai dengan profil farmakokinetika sediaan lepaskendali pada umumnya.